Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session – Second-Line GIST Patients with Mutations in KIT Exon 11 + 17/18 Only Demonstrated Substantial...
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares WALTHAM, Mass.–(BUSINESS WIRE)–Jan. 24, 2023– Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH),...
Medication Intelligence Leader Kit CheckⓇ Rebrands as BluesightⓇ The shift redefines Bluesight from a point solution to a suite of Medication Intelligence™ software products that provides a complete picture of the pharmaceutical supply chain Alexandria, VA (December...
PASSAGE BIO ANNOUNCES POSITIVE INTERIM CLINICAL DATA FROM FIRST SIX PATIENTS WITH GM1 GANGLIOSIDOSIS IN IMAGINE-1 STUDY Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profile Intra-cisterna...
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC) ARV-471 continues to show activity in heavily pre-treated patients with locally...
Recent Comments